Navigation Links
GeoVax to Exhibit at the 2009 BIO International Convention
Date:5/11/2009

Dr. Harriet Robinson to Host HIV Vaccine Panel Discussion

ATLANTA, May 11 /PRNewswire-FirstCall/ --

    WHAT:    GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based,
             publicly traded biopharmaceutical company developing human
             vaccines for diseases caused by HIV-1 (Human Immunodeficiency
             Virus) and other infectious agents to share their strategy for
             the future and plans to expand preventative trials, currently in
             Phase 2a, to proof-of-concept trials in 'at risk' humans and
             move therapeutic trials from non-human primate models to HIV-1
             virus infected individuals.

             Dr. Harriet Robinson to moderate "HIV/AIDS Vaccines: Preventative
             and Therapeutic Approaches to a Global Pandemic"

    WHERE:   2009 BIO International Convention
             Georgia Pavilion (Booth #2817)
             Georgia World Congress Center
             Atlanta, GA

    WHEN:    May 18-21, 2009
             "HIV/AIDS Vaccines: Preventative and Therapeutic Approaches to a
             Global Pandemic" Thursday, May 21, 10-11 a.m., Room B309

    WHO:     Robert McNally, Ph.D., chief executive officer and president
             Mark Reynolds, chief financial officer
             Harriet Robinson, PhD, vice president of research and development
             and developer of the GeoVax vaccine

    WHY:     HIV Vaccine Awareness Day coincides with the opening of the
             conference on May 18, and Sir Elton John delivering a keynote
             address to include how biotechnology is influencing treatment and
             prevention of the diseases.  GeoVax is looking forward to sharing
             with interested partners, investors and media its progress in
             clinical trials during the last six months and its strategy for
             the future.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. GeoVax Labs, Inc. Announces First Quarter Financial Results
2. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
3. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
4. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
5. GeoVax to Present at the BIO CEO & Investor Conference 2009
6. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Presents Data at AIDS Vaccine 2008 Conference
9. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
10. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
11. GeoVax Further Strengthens Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... , ... Stratevi, a boutique firm that partners with healthcare companies to creatively ... office in downtown Boston at 745 Atlantic Ave. , “We are seeing that ... on the value they provide, not just to patients, but also payers. Having a ...
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics and ... booth B2 at the Association for Pathology Informatics Annual Summit at ... to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research ...
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose ... lengthy trial and error process by finding the right antidepressant faster. CNSDose ... the doctor-patient relationship through a personalized approach to treatment. , A ...
(Date:5/19/2017)... , ... May 19, 2017 , ... ... Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, and who are ... and Delaware, are encouraged to submit proposals. QED, now in its tenth round, ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):